Allogene’s CAR-T could delay or prevent cancer recurrence

Allogene’s CAR-T could delay or prevent cancer recurrence

statnews.com business

Key Points:

  • Allogene Therapeutics said Monday that its off-the-shelf CAR-T treatment eliminated residual cancer cells in patients with B-cell lymphoma three times better than standard care — achieving the interim

Trending Business

Trending Technology

Trending Health